Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination.

Bone Marrow / pathology Cell Line, Tumor Cell Movement / genetics Cell Proliferation / genetics Epithelial-Mesenchymal Transition / genetics Gene Expression / genetics Humans Hypoxia / genetics Inflammation / genetics Multiple Myeloma / genetics Neoplastic Cells, Circulating / pathology Neoplastic Stem Cells / pathology Prognosis Transcription, Genetic / genetics Tumor Microenvironment / genetics

Journal

Leukemia

ISSN: 1476-5551

Titre abrégé: Leukemia

Pays: England

ID NLM: 8704895

Informations de publication

Date de publication:
02 2020

Historique:

received: 02 05 2019

accepted: 23 07 2019

revised: 25 06 2019

pubmed: 9 10 2019

medline: 5 8 2020

entrez: 10 10 2019

Statut: ppublish

Résumé

The reason why a few myeloma cells egress from the bone marrow (BM) into peripheral blood (PB) remains unknown. Here, we investigated molecular hallmarks of circulating tumor cells (CTCs) to identify the events leading to myeloma trafficking into the bloodstream. After using next-generation flow to isolate matched CTCs and BM tumor cells from 32 patients, we found high correlation in gene expression at single-cell and bulk levels (r ≥ 0.94, P = 10

Identifiants

DOI: 10.1038/s41375-019-0588-4 PMID: 31595039

pubmed: 31595039

doi: 10.1038/s41375-019-0588-4

pii: 10.1038/s41375-019-0588-4

doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

589-603

Subventions

Organisme : Cancer Research UK

Pays : United Kingdom

Références

Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046–60.

doi: 10.1056/NEJMra1011442 pubmed: 21410373 pmcid: 21410373

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2015;15:e538–48.

doi: 10.1016/S1470-2045(14)70442-5

Paiva B, Pérez-Andrés M, Vídriales MB, Almeida J, De Las Heras N, Mateos MV, et al. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma. Leukemia. 2011;25:697–706.

doi: 10.1038/leu.2010.320 pubmed: 21252988 pmcid: 21252988

Sanoja-Flores L, Flores-Montero J, Garcés JJ, Paiva B, Puig N, García-Mateo A, et al. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer J. 2018;8:117.

doi: 10.1038/s41408-018-0153-9 pubmed: 30455467 pmcid: 30455467

Kumar S, Rajkumar SV, Kyle RA, Lacy MQ, Dispenzieri A, Fonseca R, et al. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. J Clin Oncol. 2005;23:5668–74.

doi: 10.1200/JCO.2005.03.159 pubmed: 16110026 pmcid: 16110026

Bianchi G, Kyle RA, Larson DR, Witzig TE, Kumar S, Dispenzieri A, et al. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia. 2013;27:680–5.

doi: 10.1038/leu.2012.237 pubmed: 22902364 pmcid: 22902364

Gonsalves WI, Rajkumar SV, Dispenzieri A, Dingli D, Timm MM, Morice WG, et al. Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. Leukemia. 2017;31:130–5.

doi: 10.1038/leu.2016.205 pubmed: 27457702 pmcid: 27457702

Gonsalves WI, Rajkumar SV, Gupta V, Morice WG, Timm MM, Singh PP, et al. Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. Leukemia. 2014;28:2060–5.

doi: 10.1038/leu.2014.98 pubmed: 24618735 pmcid: 24618735

Gonsalves WI, Morice WG, Rajkumar V, Gupta V, Timm MM, Dispenzieri A, et al. Quantification of clonal circulating plasma cells in relapsed multiple myeloma. Br J Haematol. 2014;167:500–5.

doi: 10.1111/bjh.13067 pubmed: 25113422 pmcid: 25113422

Chakraborty R, Muchtar E, Kumar SK, Jevremovic D, Buadi FK, Dingli D, et al. Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. Haematologica. 2017;102:1439–45.

doi: 10.3324/haematol.2017.166629 pubmed: 28473618 pmcid: 28473618

Cowan AJ, Stevenson PA, Libby EN, Becker PS, Coffey DG, Green DJ, et al. Circulating plasma cells at the time of collection of autologous PBSC for transplant in multiple myeloma patients is a negative prognostic factor even in the age of post-transplant maintenance therapy. Biol Blood Marrow Transplant. 2018;24:1386–91.

doi: 10.1016/j.bbmt.2018.02.017 pubmed: 29481870 pmcid: 29481870

Foulk B, Schaffer M, Gross S, Rao C, Smirnov D, Connelly MC, et al. Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disorders. Br J Haematol. 2018;180:71–81.

doi: 10.1111/bjh.15003 pubmed: 29105742 pmcid: 29105742

Granell M, Calvo X, Garcia-Guiñón A, Escoda L, Abella E, Martínez CM, et al. Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. Haematologica. 2017;102:1099–104.

doi: 10.3324/haematol.2016.158303 pubmed: 28255016 pmcid: 28255016

Huhn S, Weinhold N, Nickel J, Pritsch M, Hielscher T, Hummel M, et al. Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial. Bone Marrow Transplant. 2017;52:1194–8.

doi: 10.1038/bmt.2017.91 pubmed: 28504661 pmcid: 28504661

Dingli D, Nowakowski GS, Dispenzieri A, Lacy MQ, Hayman SR, Rajkumar SV, et al. Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system. Blood. 2006;107:3384–8.

doi: 10.1182/blood-2005-08-3398 pubmed: 16339399 pmcid: 16339399

Paiva B, Paino T, Sayagues JM, Garayoa M, San-Segundo L, Martín M, et al. Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood. 2013;122:3591–8.

doi: 10.1182/blood-2013-06-510453 pubmed: 24072855 pmcid: 24072855

Masri S, Sassone-Corsi P. The emerging link between cancer, metabolism, and circadian rhythms. Nat Med. 2018;24:1795–803.

doi: 10.1038/s41591-018-0271-8 pubmed: 30523327 pmcid: 30523327

Méndez-Ferrer S, Lucas D, Battista M, Frenette PS. Haematopoietic stem cell release is regulated by circadian oscillations. Nature. 2008;452:442–7.

doi: 10.1038/nature06685 pubmed: 18256599 pmcid: 18256599

Ghobrial IM. Myeloma as a model for the process of metastasis: implications for therapy. Blood. 2012;120:20–30.

doi: 10.1182/blood-2012-01-379024 pubmed: 22535658 pmcid: 22535658

Mishima Y, Paiva B, Shi J, Park J, Manier S, Takagi S, et al. The mutational landscape of circulating tumor cells in multiple myeloma. Cell Rep. 2017;19:218–24.

doi: 10.1016/j.celrep.2017.03.025 pubmed: 28380360 pmcid: 28380360

Lohr JG, Kim S, Gould J, Knoechel B, Drier Y, Cotton MJ, et al. Genetic interrogation of circulating multiple myeloma cells at single-cell resolution. Sci Transl Med. 2016;8:1–10.

doi: 10.1126/scitranslmed.aac7037

Ledergor G, Weiner A, Zada M, Wang S-Y, Cohen YC, Gatt ME, et al. Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. Nat Med. 2018;24:1867–76.

doi: 10.1038/s41591-018-0269-2 pubmed: 30523328 pmcid: 30523328

Flores-Montero J, Flores LS, Paiva B, Puig N, García-Sánchez O, Böttcher S, et al. Next generation flow (NGF) for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31:2094–103.

doi: 10.1038/leu.2017.29 pubmed: 28104919 pmcid: 28104919

Puig N, Paiva B, Lasa M, Burgos L, Perez JJ, Merino J, et al. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis. Leukemia. 2019;33:1256–67.

doi: 10.1038/s41375-018-0308-5 pubmed: 30542145 pmcid: 30542145

Fu GK, Wilhelmy J, Stern D, Fan HC, Fodor SPA. Digital encoding of cellular mRNAs enabling precise and absolute gene expression measurement by single-molecule counting. Anal Chem. 2014;86:2867–70.

doi: 10.1021/ac500459p pubmed: 24579851 pmcid: 24579851

Cole M, Risso D (2019). scone: Single Cell Overview of Normalized Expression data. R package version 1.8.0. https://doi.org/10.18129/B9.bioc.scone .

Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol. 2018;36:411–20.

doi: 10.1038/nbt.4096 pubmed: 29608179 pmcid: 29608179

Schlitzer A, Sivakamasundari V, Chen J, Sumatoh HR, Schreuder J, Lum J, et al. Identification of cDC1- and cDC2-committed DC progenitors reveals early lineage priming at the common DC progenitor stage in the bone marrow. Nat Immunol. 2015;16:718–28.

doi: 10.1038/ni.3200 pubmed: 26054720 pmcid: 26054720

Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.

doi: 10.1093/nar/gkv007 pubmed: 4402510 pmcid: 4402510

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545–50.

doi: 10.1073/pnas.0506580102

Raimondi L, Amodio N, Teresa M, Martino D, Altomare E, Leotta M, et al. Targeting of multiple myeloma-related angiogenesis by miR- 199a-5p mimics: in vitro and in vivo anti-tumor activity. Oncotarget. 2014;5:3039–54.

doi: 10.18632/oncotarget.1747 pubmed: 4102790 pmcid: 4102790

Alboukadel Kassambara (2019). ggpubr: ‘ggplot2’ Based Publication Ready Plots. R package version 0.2.1. https://CRAN.R-project.org/package=ggpubr .

Jaitin DA, Kenigsberg E, Keren-Shaul H, Elefant N, Paul F, Zaretsky I, et al. Massively parallel single-cell RNA-seq for marker-free decomposition of tissues into cell types. Science. 2014;343:776–9.

doi: 10.1126/science.1247651 pubmed: 24531970 pmcid: 24531970

Lavin Y, Kobayashi S, Leader A, Amir ED, Elefant N, Bigenwald C, et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell. 2017;169:750–7. e17

doi: 10.1016/j.cell.2017.04.014 pubmed: 28475900 pmcid: 28475900

Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.

doi: 10.1186/s13059-014-0550-8 pubmed: 25516281 pmcid: 25516281

Therneau T (2015). A Package for Survival Analysis in S. R package version 2.38. https://CRAN.R-project.org/package=survival .

Alboukadel Kassambara and Marcin Kosinski (2019). survminer: Drawing Survival Curves using ‘ggplot2’. R package version 0.4.4. https://CRAN.R-project.org/package=survminer .

McKenzie CW, Craige B, Kroeger TV, Finn R, Wyatt TA, Sisson JH, et al. CFAP54 is required for proper ciliary motility and assembly of the central pair apparatus in mice. Mol Biol Cell. 2015;26:3140–9.

doi: 10.1091/mbc.e15-02-0121 pubmed: 4569307 pmcid: 4569307

Martin TA, Harrison G, Mansel RE, Jiang WG. The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol. 2003;46:165–86.

doi: 10.1016/S1040-8428(02)00172-5 pubmed: 12711360 pmcid: 12711360

Ivetic A, Ridley AJ. Ezrin/radixin/moesin proteins and Rho GTPase signalling in leucocytes. Immunology. 2004;112:165–76.

doi: 10.1111/j.1365-2567.2004.01882.x pubmed: 15147559 pmcid: 15147559

Zhu Y, Zhu MX, Zhang XD, Xu XE, Wu ZY, Liao LD, et al. SMYD3 stimulates EZR and LOXL2 transcription to enhance proliferation, migration, and invasion in esophageal squamous cell carcinoma. Hum Pathol. 2016;52:153–63.

doi: 10.1016/j.humpath.2016.01.012 pubmed: 26980013 pmcid: 26980013

Hsieh Y-H, Chou R-H, Hsieh S-C, Cheng C-W, Lin C-L, Yang S-F, et al. Targeting EMP3 suppresses proliferation and invasion of hepatocellular carcinoma cells through inactivation of PI3K/Akt pathway. Oncotarget. 2015;6:34859–74.

pubmed: 26472188 pmcid: 26472188

Dumitru CA, Bankfalvi A, Gu X, Zeidler R, Brandau S, Lang S. AHNAK and inflammatory markers predict poor survival in laryngeal carcinoma. PLoS ONE. 2013;8:e56420.

Davis TA, Loos B, Engelbrecht A-M. AHNAK: the giant jack of all trades. Cell Signal. 2014;26:2683–93.

doi: 10.1016/j.cellsig.2014.08.017 pubmed: 25172424 pmcid: 25172424

Paiva B, Corchete LA, Vidriales M-B, Puig N, Maiso P, Rodriguez I, et al. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. Blood. 2016;127:1896–906.

doi: 10.1182/blood-2015-08-665679 pubmed: 26755711 pmcid: 26755711

Waldschmidt JM, Simon A, Wider D, Müller SJ, Follo M, Ihorst G, et al. CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma. Br J Haematol. 2017;179:36–49.

doi: 10.1111/bjh.14807 pubmed: 28670693 pmcid: 28670693

Anreddy N, Hazlehurst LA. Targeting intrinsic and extrinsic vulnerabilities for the treatment of multiple myeloma. J Cell Biochem. 2017;118:15–25.

doi: 10.1002/jcb.25617 pubmed: 27261328 pmcid: 27261328

Storti P, Marchica V, Giuliani N. Role of galectins in multiple myeloma. Int J Mol Sci. 2017;18:2740.

doi: 10.3390/ijms18122740

Glavey SV, Naba A, Manier S, Clauser K, Tahri S, Park J, et al. Proteomic characterization of human multiple myeloma bone marrow extracellular matrix. Leukemia. 2017;31:2426–34.

doi: 10.1038/leu.2017.102 pubmed: 28344315 pmcid: 28344315

Ma Y, Jin Z, Huang J, Zhou S, Ye H, Jiang S, et al. IQGAP1 plays an important role in the cell proliferation of multiple myeloma via the MAP kinase (ERK) pathway. Oncol Rep. 2013;30:3032–8.

doi: 10.3892/or.2013.2785 pubmed: 24101133 pmcid: 24101133

Gocke CB, McMillan R, Wang Q, Begum A, Penchev VR, Ali SA, et al. IQGAP1 scaffold-MAP kinase interactions enhance multiple myeloma clonogenic growth and self-renewal. Mol Cancer Ther. 2016;15:2733–9.

doi: 10.1158/1535-7163.MCT-16-0323 pubmed: 27573425 pmcid: 27573425

Aust G, Zhu D, Van Meir EG, Xu L. Adhesion GPCRs in tumorigenesis. Handb Exp Pharmacol. 2016;234:369–96.

doi: 10.1007/978-3-319-41523-9_17 pubmed: 27832497 pmcid: 27832497

Demchenko YN, Glebov OK, Zingone A, Keats JJ, Bergsagel PL, Kuehl WMClassical. and/or alternative NF-kB pathway activation in multiple myeloma. Cancer. 2010;115:3541–52.

Troppan K, Hofer S, Wenzl K, Lassnig M, Pursche B, Steinbauer E, et al. Frequent down regulation of the tumor suppressor gene A20 in multiple myeloma. PLoS ONE. 2015;10:e0123922.

doi: 10.1371/journal.pone.0123922 pubmed: 25856582 pmcid: 25856582

Broyl A, Hose D, Lokhorst H, De Knegt Y, Peeters J, Jauch A, et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Gene Expr. 2010;116:2543–53.

Li D, Wu C, Cai Y, Liu B. Association of NFKB1 and NFKBIA gene polymorphisms with susceptibility of gastric cancer. Tumor Biol. 2017;39:1–6.

Zhang M, Huang J, Tan X, Bai J, Wang H, Ge Y, et al. Common polymorphisms in the NFKBIA gene and cancer susceptibility: a meta-analysis. Med Sci Monit. 2015;21:3186–96.

doi: 10.12659/MSM.895257 pubmed: 26488500 pmcid: 26488500

Wang Q, Wang X, Liang Q, Wang S, Xiwen L, Pan F, et al. Distinct prognostic value of mRNA expression of guanylate-binding protein genes in skin cutaneous melanoma. Oncol Lett. 2018;15:7914–22.

pubmed: 29725478 pmcid: 29725478

Godoy P, Cadenas C, Hellwig B, Marchan R, Stewart J, Reif R, et al. Interferon-inducible guanylate binding protein (GBP2) is associated with better prognosis in breast cancer and indicates an efficient T cell response. Breast Cancer. 2014;21:491–9.

doi: 10.1007/s12282-012-0404-8 pubmed: 23001506 pmcid: 23001506

Thijssen VL, Heusschen R, Caers J, Griffioen AW. Galectin expression in cancer diagnosis and prognosis: a systematic review. Biochim Biophys Acta. 2015;1855:235–47.

pubmed: 25819524 pmcid: 25819524

Cheng CL, Hou HA, Lee MC, Liu CY, Jhuang JY, Lai YJ, et al. Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia. Blood. 2013;121(Apr):3172–80.

doi: 10.1182/blood-2012-07-443762 pubmed: 23449638 pmcid: 23449638

Albright RA, Chang WC, Robert D, Ornstein DL, Cao W, Liu L, et al. NPP4 is a procoagulant enzyme on the surface of vascular endothelium. Blood. 2012;120:4432–40.

doi: 10.1182/blood-2012-04-425215 pubmed: 22995898 pmcid: 22995898

Xu X, Han K, Zhu J, Mao H, Lin X, Zhang Z, et al. An inhibitor of cholesterol absorption displays anti-myeloma activity by targeting the JAK2-STAT3 signaling pathway. Oncotarget. 2016;7:75539–50.

pubmed: 27705908 pmcid: 27705908

Murai T. Cholesterol lowering: role in cancer prevention and treatment. Biol Chem. 2015;396:1–11.

doi: 10.1515/hsz-2014-0194 pubmed: 25205720 pmcid: 25205720

Silvente-Poirot S, Poirot M. Cancer. Cholesterol and cancer, in the balance. Science. 2014;343:1445–6.

doi: 10.1126/science.1252787 pubmed: 24675946 pmcid: 24675946

Cohen Y, Gutwein O, Garach-Jehoshua O, Bar-Haim A, Kornberg A. The proliferation arrest of primary tumor cells out-of-niche is associated with widespread downregulation of mitotic and transcriptional genes. Hematology. 2014;19:286–92.

doi: 10.1179/1607845413Y.0000000125 pubmed: 24074379 pmcid: 24074379

Deng Y, Jiang L, Wang Y, Xi Q, Zhong J, Liu J, et al. High expression of CDC6 is associated with accelerated cell proliferation and poor prognosis of epithelial ovarian cancer. Pathol Res Pract. 2016;212:239–46.

doi: 10.1016/j.prp.2015.09.014 pubmed: 26920249 pmcid: 26920249

Avigdor A, Goichberg P, Shivtiel S, Dar A, Peled A, Samira S, et al. CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood. 2004;103:2981–9.

doi: 10.1182/blood-2003-10-3611 pubmed: 15070674 pmcid: 15070674

Dimitroff CJ, Lee JY, Rafii S, Fuhlbrigge RC, Sackstein R. CD44 is a major E-selectin ligand on human hematopoietic progenitor cells. J Cell Biol. 2001;153:1277–86.

doi: 10.1083/jcb.153.6.1277 pubmed: 11402070 pmcid: 11402070

Kodama H, Murata S, Ishida M, Yamamoto H, Yamaguchi T, Kaida S, et al. Prognostic impact of CD44-positive cancer stem-like cells at the invasive front of gastric cancer. Br J Cancer. 2017;116:186–94.

doi: 10.1038/bjc.2016.401 pubmed: 27931044 pmcid: 27931044

Chanmee T, Ontong P, Kimata K, Itano N. Key roles of hyaluronan and its CD44 receptor in the stemness and survival of cancer stem cells. Front Oncol. 2015;5:180.

doi: 10.3389/fonc.2015.00180 pubmed: 26322272 pmcid: 26322272

Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015;33:2863–9.

doi: 10.1200/JCO.2015.61.2267 pubmed: 26240224 pmcid: 26240224

Storti P, Marchica V, Airoldi I, Donofrio G, Fiorini E, Ferri V, et al. Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo. Leukemia. 2016;30:2351–63.

doi: 10.1038/leu.2016.137

Takagi S, Tsukamoto S, Park J, Johnson KE, Kawano Y, Moschetta M, et al. Platelets enhance multiple myeloma progression via il-1b upregulation. Clin Cancer Res. 2018;24:2430–9.

doi: 10.1158/1078-0432.CCR-17-2003 pubmed: 29440174 pmcid: 29440174

Leblanc R, Peyruchaud O. Metastasis: new functional implications of platelets and megakaryocytes. Blood. 2016;128:24–31.

doi: 10.1182/blood-2016-01-636399 pubmed: 27154188 pmcid: 27154188

Dongre A, Weinberg RA. New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20:69–84.

doi: 10.1038/s41580-018-0080-4 pubmed: 30459476 pmcid: 30459476

Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23:1124–34.

doi: 10.1038/nm.4409

Zhang H, Brown RL, Wei Y, Zhao P, Liu S, Liu X, et al. CD44 splice isoform switching determines breast cancer stem cell state. Genes Dev. 2019;33:1–14.

doi: 10.1101/gad.322990.118

Misra S, Heldin P, Hascall VC, Karamanos NK, Skandalis SS, Markwald RR, et al. Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J. 2011;278:1429–43.

doi: 10.1111/j.1742-4658.2011.08071.x pubmed: 21362138 pmcid: 21362138

Mueller N, Wicklein D, Eisenwort G, Jawhar M, Berger D, Stefanzl G, et al. CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis. Blood. 2018;132:1936–50.

doi: 10.1182/blood-2018-02-833582 pubmed: 30018080 pmcid: 30018080

Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H, et al. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia. 2014;28:373–83.

doi: 10.1038/leu.2013.174 pubmed: 23760401 pmcid: 23760401

Yan Y, Zuo X, Wei D. Concise review: emerging role of CD44 in cancer stem cells: a promising biomarker and therapeutic target. Stem Cells Transl Med. 2015;4:1033–43.

doi: 10.5966/sctm.2015-0048 pubmed: 26136504 pmcid: 26136504

Natoni A, Smith TAG, Keane N, McEllistrim C, Connolly C, Jha A, et al. E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271. Leukemia. 2017;31:2642–51.

doi: 10.1038/leu.2017.123 pubmed: 28439107 pmcid: 28439107

Lytle NK, Barber AG, Reya T. Stem cell fate in cancer growth, progression and therapy resistance. Nat Rev Cancer. 2018;18:669–80.

doi: 10.1038/s41568-018-0056-x pubmed: 30228301 pmcid: 30228301

Roccaro AM, Mishima Y, Sacco A, Moschetta M, Tai Y-T, Shi J, et al. CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation. Cell Rep. 2015;12:622–35.

doi: 10.1016/j.celrep.2015.06.059 pubmed: 26190113 pmcid: 26190113

Peacock CD, Wang Q, Gesell GS, Corcoran-Schwartz IM, Jones E, Kim J, et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci USA 2007;104:4048–53.

doi: 10.1073/pnas.0611682104 pubmed: 17360475 pmcid: 17360475

Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, et al. Characterization of clonogenic multiple myeloma cells. Blood. 2004;103:2332–6.

doi: 10.1182/blood-2003-09-3064 pubmed: 14630803 pmcid: 14630803

Thiago LS, Perez-Andres M, Balanzategui A, Sarasquete ME, Paiva B, Jara-Acevedo M, et al. Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica. 2014;99:155–62.

doi: 10.3324/haematol.2013.092817 pubmed: 23872308 pmcid: 23872308

Li H, Zhong A, Li S, Meng X, Wang X, Xu F, et al. The integrated pathway of TGFβ/Snail with TNFα/NFκB may facilitate the tumor-stroma interaction in the EMT process and colorectal cancer prognosis. Sci Rep. 2017;7:4915.

doi: 10.1038/s41598-017-05280-6 pubmed: 28687755 pmcid: 28687755

Manzi M, Bacigalupo ML, Carabias P, Elola MT, Wolfenstein-Todel C, Rabinovich GA, et al. Galectin-1 controls the proliferation and migration of liver sinusoidal endothelial cells and their interaction with hepatocarcinoma cells. J Cell Physiol. 2016;231:1522–33.

doi: 10.1002/jcp.25244 pubmed: 26551914 pmcid: 26551914